Danshensu (sodium)

Danshensu (Dan shen suan A) sodium, an orally active phenolic compound, can induce Nrf2/HO-1 activation and inhibition of NF-κB pathway. Danshensu sodium reduces reactive oxygen species (ROS) production, upregulates antioxidant defense mechanism and inhibits intrinsic apoptotic pathway. Danshensu sodium displays a potent antiviral activity against SARS-CoV-2 with EC50 of 0.97 μM. Danshensu sodium has anti-oxidation, anti-apoptosis, anti-lung inflammatory and has the potential for COVID-19, cardiovascular and cerebrovascular diseases research[1][2][3].

Product Specifications

CAS Number

[81075-52-7]

Product Name Alternative

Dan shen suan A (sodium) ; Salvianic acid A (sodium)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Keap1-Nrf2; NF-κB; Reactive Oxygen Species (ROS) ; SARS-CoV

Type

Natural Products

Related Pathways

Anti-infection; Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

Applications

COVID-19-anti-virus

Field of Research

Cancer; Infection; Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/danshensu-sodium.html

Purity

99.9

Solubility

H2O : 50 mg/mL (ultrasonic)

Smiles

O=C(O[Na])[C@H](O)CC1=CC(O)=C(C=C1)O

Molecular Formula

C9H9NaO5

Molecular Weight

220.15

Precautions

H302, H315, H319, H335

References & Citations

[1]Wei Wang, et al. Danshensu alleviates pseudo-typed SARS-CoV-2 induced mouse acute lung inflammation. Acta Pharmacol Sin. 2022 Apr;43 (4) :771-780. |[2]V Bharath Kumar, et al. Sodium Danshensu Inhibits Oral Cancer Cell Migration and Invasion by Modulating p38 Signaling Pathway. Front Endocrinol (Lausanne) . 2020 Sep 30:11:568436. |[3]Chen Yu, et al. Danshensu attenuates cisplatin-induced nephrotoxicity through activation of Nrf2 pathway and inhibition of NF-κB. Biomed Pharmacother. 2021 Oct:142:111995.

Shipping Conditions

Blue Ice

Storage Conditions

-20°C (Powder, protect from light, stored under nitrogen)

Scientific Category

Natural Products

Clinical Information

No Development Reported

Citation 01

Eur J Pharmacol. 2025 Feb 1:177296.|Breast Cancer Res Treat. 2024 Dec;208 (3) :657-671.|Cancer Immunol Immunother. 2025 Jun 30;74 (8) :256.|J Tradit Complement Med. 2025 Feb 7;15 (4) :434-445.|Phytomedicine. 2023 May:113:154743.